This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human S100A10 Protein, His Tag
catalog :
S10-H5127
quantity :
100 ug, 1 mg
price :
300 USD, 1980 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
S10-H5127
product name :
Human S100A10 Protein, His Tag
quantity :
100 ug, 1 mg
price :
300 USD, 1980 USD
quantity & price :
$300/100ug,$1980/1mg (500ug × 2)
target :
S100A10
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human S100A10, His Tag (S10-H5127) is expressed from E.coli cells. It contains AA Met 1 - Lys 97 (Accession # AAH15973).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human S100A10, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
S100 calcium-binding protein A10 (S100A10), a member of the S100 family of proteins containing two EF-hand calcium-binding motifs, is also known as protein S100-A10, calpactin I light chain, cellular ligand of annexin II, p10 protein and p11, which can be found as a free monomer, a homodimer, or a heterotetramer composed of a p11 dimer complex with two molecules of annexin II. S100A10 is an integral part of cellular structural scaffolding that interacts with plasma membrane proteins through its association with annexin II. S100A10 also works together with cytosolic and peripheral membrane-associated proteins such as AHNAK in the development of the intracellular membrane. Furthermore,S100A10 has been implicated in the transportation of proteins involved in mood regulation, nociception, and cell polarization. Complexed with the annexin II, S100A10 binds receptor and channel proteins and guides them to the cell surface, resulting in increased membrane localization and consequent magnified functional expression of these proteins.
References :
(1) Harder T., et al., 1992,Gene. 113(2):269-74.
(2) Choudhary C., et al., 2009, Science 325:834-840.
(3) Rety S., et al., 1999, Nat. Struct. Biol. 6:89-95.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments